Tag: Sleep Apnea

SAN DIEGO – Sleep apnea sufferers can gain health benefits from PAP treatment in as little as two hours per night, according to a study led by ResMed and presented at the American Thoracic Society’s annual international conference.  Researchers found:  The minimum PAP usage threshold for benefit was two to three hours per night (up to 50% lower than the four hours required by CMS and many private insurers to prove adherence);  Benefits begin at two hours of nightly...

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has raised $62.5 million of committed capital in a Series C financing led by new investor Sectoral Asset Management. “Patients with obstructive sleep apnea are in need of new pharmaceutical treatment options to manage this serious, life-altering, and life-threatening disease,” said Larry Miller, M.D., CEO...

BRISBANE, Australia – Oventus Medical’s direct-to-consumer market model reached its first optimization milestone in the third quarter of its fiscal year 2022: It delivered growth in active leads with a reduction in advertising spend of 20% less than the previous quarter, the company has announced. Despite the March quarter being slow due to seasonality, Oventus says new leads increased 63% with 6,100 generated. “With the weakest of insurance seasonality period behind us, we...

IRVINE, Calif. – Oventus Medical has reported interim financial results for the six months ended Dec. 31, 2021, including $554,000 in revenue. The company, which makes the O2Vent oral device to treat obstructive sleep apnea, also reported cash receipts totaling $497,000, up 20% compared to the same period in 2020. “We are very encouraged by the way the move to direct-to-consumer marketing has resulted in substantial growth of the prospective customer pipeline,” said John Cox, who...

COLUMBIA, Mo. – CPAP therapy may not be as effective for patients older than 80, say researchers from the University of Missouri School of Medicine. In a study published in Sleep Medicine, researchers studied 369 participants over the age of 70 with OSA and assigned roughly half to receive CPAP therapy for three months. Researchers used several metrics to compare both groups, including a subjective measure of a patient’s sleepiness, the effect of CPAP on sleep-related quality of life,...

TAMPA, Fla. – RemSleep Holdings has partnered with Preya Co. and MCAP Mediawire to maximize its communication and exposure with current and potential shareholders, as well as refine and broaden its overall messaging and outreach. The move comes as the company prepares to get its DeltaWave nasal CPAP interface approved by the U.S. Food and Drug Administration and launched to market. “We feel we owe it to our current and future investors to have partnered with a gold star firm to assist...

HIGHLANDS RANCH, Colo. – Vivos Therapeutics saw an 18-times increase in the total number of SleepImage Home Sleep Apnea Tests given across its network of trained dentists (known as Vivos Integrated Practices or VIPs) for the three months ended Dec. 31, 2021. The company also reported a 5.7-times increase in the number of VIPs administering HSTs; and a 3-times increase in the average number of HSTs being administered per VIP. “We have always believed that the pathway to getting more patients...

HOUSTON and NEW YORK – CPAP.com has received a strategic investment from global investment firm Cathay Capital, the company announced today.  CPAP.com will benefit from Cathay Capital’s support as it accelerates its development and strengthens its leadership position in the field of sleep apnea treatment.   “We’re honored to partner with the entire Cathay Capital team to guide us in driving the next phase of our growth,” said Johnny Goodman, co-founder...

CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has announced positive topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, three-period crossover study (protocol APX-001) in patients with OSA evaluating AD504 and AD182. Patients treated with AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in AHI from placebo, which...

DARIEN, Ill. – The American Academy of Sleep Medicine will use a new grant from the Centers for Disease Control to reach the millions of Americans who don’t know they have obstructive sleep apnea, says Dr. Raman Malhotra, president.  “OSA is very common and although we tend to see lots of patients in clinic, it’s interesting that 80% are undiagnosed,” he said. “Millions of Americans don’t even know the symptoms or don’t know what to do if they...